Skip to main content

Table 1 Demographic details of 1 L platinum eligible patients with R/M SCCHN

From: Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

  Overall France Germany Italy Spain UK
Number of physicians 195 31 66 50 32 16
Number of patients 577 114 117 130 117 99
Number of caregivers 238 81 53 21 38 45
Age
 Mean (SD) years 62.8 (8.5) 62.9 (8.6) 64.2 (7.2) 61.6 (9.6) 60.8 (8.6) 64.9 (7.4)
 Under 65 years (%) 53.6 50.0 50.4 60.8 63.2 40.4
 65 years and over (%) 46.4 50.0 49.6 39.2 36.8 59.6
Gender (%)
 Male 72.3 83.3 64.1 72.3 72.6 68.7
Staging at initial diagnosis (%)
 Stage I 1.0 1.8 1.7 0.8 0.9 0.0
 Stage II 10.9 6.1 6.0 17.7 14.5 9.1
 Stage III 23.2 27.2 2.6 36.9 30.8 16.2
 Stage IVA 11.4 12.3 6.8 11.5 19.7 6.1
 Stage IVB 5.9 3.5 9.4 8.5 4.3 3.0
 Stage IVC 47.3 49.1 73.5 24.6 29.9 64.6
Current staging (%)
 Stage III 5.7 2.6 3.4 12.3 7.7 1.0
 Stage IVA 14.7 21.9 0.9 20.0 20.5 9.1
 Stage IVB 13.9 12.3 8.5 20.8 17.9 8.1
 Stage IVC 65.7 63.2 87.2 46.9 53.8 81.8
ECOG score at initial diagnosis (%)
 0–1 86.2 76.3 95.8 80.0 84.6 96.0
 0 27.4 11.4 47.9 28.5 22.2 26.3
 1 58.8 64.9 47.9 51.5 62.4 69.7
 2+ 13.5 23.7 4.3 18.5 15.4 4.0
Current ECOG score (%)
 0–1 78.6 59.6 88.0 76.1 80.3 89.9
 0 12.7 2.6 18.8 12.3 8.5 22.2
 1 65.9 57.0 69.2 63.8 71.8 67.7
 2 21.5 40.4 12.0 23.8 19.7 10.1
Primary tumour site (%)
 Oral cavity 31.9 28.1 35.9 31.5 34.2 29.3
 Oropharynx 26.7 38.6 17.9 20.0 23.1 36.4
 Hypopharynx 17.0 21.1 12.0 13.1 18.8 21.2
 Larynx 23.9 12.3 33.3 34.6 23.9 12.1
  1. ECOG = Eastern Cooperative Oncology Group performance status